meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1)
2
mCRC - 2nd line (L2)
3
endometrial cancer
10
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
avelumab based treatment
avelumab plus SoC
dostarlimab based treatment
dostarlimab plus soC
durvalumab based treatment
durvalumab plus olaparib plus SoC
durvalumab plus SoC
pembrolizumab based treatment
pembrolizumab plus lenvatinib
pembrolizumab plus SoC
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
VEGF(R) inhibitor
lenvatinib
lenvatinib in association
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
durvalumab based treatment
durvalumab plus olaparib plus SoC
durvalumab plus SoC
Comparator:
vs placebo plus SoC;
Risk of bias:
low;
some concerns;
high;
NA;